Identifying patient subgroups that are most likely to benefit from medications used to treat alcohol use disorder
确定最有可能从用于治疗酒精使用障碍的药物中受益的患者亚组
基本信息
- 批准号:10698725
- 负责人:
- 金额:$ 15.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-02-01 至 2026-01-31
- 项目状态:未结题
- 来源:
- 关键词:AbstinenceAddressAdoptionAffectAlcohol consumptionAmbulatory CareAwardCharacteristicsChronic DiseaseClinical TrialsCompetenceConduct Clinical TrialsDataData SourcesDatabasesDevelopment PlansDiseaseEffectivenessEnvironmentEpidemiologyEvaluationExclusion CriteriaFrequenciesGoalsHealthHealth PersonnelHealth ServicesHeavy DrinkingHospitalsIndividualInterventionLabelLiteratureMeasuresMedicalMedicareMedicineMentored Research Scientist Development AwardMentorsMentorshipMethodologyMethodsNational Institute on Alcohol Abuse and AlcoholismObservational StudyOutcomeOutcome MeasurePatientsPersonsPharmaceutical PreparationsPharmacoepidemiologyPublic HealthPublic Health SchoolsPublishingResearchResearch MethodologyResearch PersonnelRiskSample SizeSamplingStatistical Data InterpretationStrategic PlanningSubgroupTechniquesTestingTimeTrainingUncertaintyUnited StatesUnited States Food and Drug AdministrationWorkWorld Health Organizationaddictionalcohol responsealcohol use disordercare outcomescareer developmentclinical careclinical decision-makingclinical practicedrinkingevidence baseimprovedinnovationmultiple data sourcesnovelpatient subsetspersonalized decisionprofessorprogramspsychosocialstatistical learning
项目摘要
PROJECT SUMMARY/ABSTRACT
The objective of this K01 award is to provide Dr. Joshua Wallach, an Assistant Professor of Epidemiology at
the Yale School of Public Health, with the protected time necessary to become an independent expert in
synthesizing, evaluating, and establishing the best evidence to inform clinical practice in the field of alcohol use
disorder (AUD). Although AUD is a common and morbid disease, for which medication treatment is available,
uncertainties about whether and for whom treatments work may be causing AUD medication underutilization.
To advance the evidence base to support AUD medication treatment, research is needed to identify patient
subgroups that are most likely to benefit from each medication used to treat AUD. However, traditional
subgroup analyses often consider only one patient characteristic at a time and are conducted in small clinical
trials with strict exclusion criteria, short durations, and outcomes that may not reflect how patients feel or
function. This proposed K01 will address these limitations by conducting subgroup analyses using multiple
data sources, outcomes, and analytical techniques. In Aim 1, Dr. Wallach will identify and assess the validity of
already published subgroup analyses to establish promising patient subgroups that are most likely to benefit
from each medication used to treat AUD. In Aim 2, existing data from the largest AUD trial in the US (the
COMBINE study) will be used to (a) corroborate promising patient subgroup differences identified in Aim 1 and
(b) explore new differences between patient subgroups, using multiple methods (i.e. traditional and statistical
learning, which can consider multiple characteristics) and outcome measures (abstinence, heavy drinking, and
2-shift reduction in World Health Organization drinking levels). In Aim 3, claims data from OptumLabs, a
database of over 150 million privately insured and Medicare Advantage enrollees, will be used to determine
whether the same, similar, or new differences between patient subgroups are observed in real-world settings
when hospital and ambulatory care outcomes are considered. These aims will clarify uncertainties among
patients and clinicians regarding the adoption of AUD medications, which can decrease the public health
burden associated with AUD. To support these aims, Dr. Wallach’s career development plan will include
training in: (1) AUD medications and addiction medicine, (2) novel statistical learning techniques that can be
used to inform individualized clinical decision making, and (3) pharmacoepidemiology and observational
research methods for real-world medical product evaluation. The candidate has identified an interdisciplinary
team of mentors and advisors, including co-primary mentors Dr. Joseph Ross, a health services researcher
and administrative data expert, and Dr. Stephanie O’Malley, an AUD treatment and addiction medicine expert.
The Yale Schools of Public Health and Medicine provide the ideal environment for career development. This
K01 will prepare Dr. Wallach for an R01 submission, and will facilitate his long-term goal of developing an
innovative research program combining meta-research and real-world evaluation to improve AUD clinical care.
项目摘要/摘要
这一K01奖项的目的是为约书亚·沃拉赫博士提供流行病学助理教授
耶鲁大学公共卫生学院,拥有成为独立专家所需的保护时间
为酒精使用领域的临床实践提供信息的最佳证据的合成、评估和建立
精神障碍(澳元)。虽然AUD是一种常见和病态的疾病,药物治疗是可用的,
关于治疗是否有效以及对谁有效的不确定性可能导致AUD药物利用不足。
为了推进支持AUD药物治疗的证据基础,需要进行研究来识别患者
最有可能从治疗AUD的每种药物中受益的亚组。然而,传统的
亚组分析通常一次只考虑一个患者的特征,并在小型临床中进行
试验排除标准严格,持续时间短,结果可能不能反映患者的感受或
功能。建议的K01将通过使用多个
数据来源、结果和分析技术。在目标1中,Wallach博士将识别和评估
已经发表的分组分析,以建立最有可能受益的有前途的患者亚组
从每一种用于治疗澳门氏症的药物中。在AIM 2中,来自美国最大的AUD试验(The
联合研究)将用于(A)证实目标1和目标1中确定的有希望的患者亚组差异
(B)使用多种方法(即传统方法和统计方法)探索患者分组之间的新差异
学习,可以考虑多个特征)和结果衡量标准(禁欲、酗酒和
2--减少世界卫生组织饮酒水平)。在AIM 3中,声称来自OptomLabs的数据,一个
超过1.5亿私人保险和Medicare Advantage投保人的数据库将用于确定
无论患者亚组之间的差异是相同的、相似的还是新的,在现实世界中都可以观察到
当考虑到医院和门诊护理的结果时。这些目标将澄清以下方面的不确定性
患者和临床医生对使用AUD药物的态度,这可能会降低公共健康
与澳元相关的负担。为了支持这些目标,沃拉赫博士的职业发展计划将包括
培训:(1)AUD药物和成瘾药物,(2)新的统计学习技术
用于指导个体化临床决策,以及(3)药物流行病学和观察学
真实世界医疗产品评价的研究方法。候选人已经确定了一个跨学科的
导师和顾问团队,包括共同的小学导师约瑟夫·罗斯博士,一名卫生服务研究员
和行政数据专家,以及斯蒂芬妮·奥马利博士,AUD治疗和成瘾医学专家。
耶鲁大学公共卫生和医学院为职业发展提供了理想的环境。这
K01将为Wallach博士的R01提交做准备,并将促进他开发一种
结合元研究和真实世界评估的创新研究计划,以改善AUD临床护理。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joshua David Wallach其他文献
Joshua David Wallach的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joshua David Wallach', 18)}}的其他基金
Identifying Patient Subgroups That Are Most Likely To Benefit From Medications Used To Treat Alcohol Use Disorder
确定最有可能从用于治疗酒精使用障碍的药物中受益的患者亚组
- 批准号:
10334521 - 财政年份:2021
- 资助金额:
$ 15.74万 - 项目类别:
Identifying patient subgroups that are most likely to benefit from medications used to treat alcohol use disorder
确定最有可能从用于治疗酒精使用障碍的药物中受益的患者亚组
- 批准号:
10555243 - 财政年份:2021
- 资助金额:
$ 15.74万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 15.74万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 15.74万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 15.74万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 15.74万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 15.74万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 15.74万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 15.74万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 15.74万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 15.74万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 15.74万 - 项目类别:
Research Grant